Closed C$4.27: WELL.TO WELL Health (TSX) 17 Mar 2026 earnings catalysts

WELL.TO stock closed at C$4.27 on the TSX on 17 Mar 2026 as the market priced in WELL Health’s upcoming earnings announcement on 19 Mar 2026. Trading volume reached 1,525,635.00 shares, above the 1,339,801.00 average, signaling elevated interest. Investors will watch revenue trends, progress on the WELLSTAR spin-out, and margin guidance as potential catalysts for the next move in Canada’s digital healthcare group.

WELL.TO stock: Market close and short-term price action

WELL.TO stock ended the session at C$4.27, up C$0.10 or 2.40% from the previous close of C$4.17. Day range was C$4.20–C$4.34, with a 52-week range of C$3.58–C$6.08. Volume at 1,525,635.00 shares represented a relative volume of 1.14, showing above-average participation.

The 50-day moving average sits at C$4.11 and the 200-day at C$4.41, putting the stock slightly below longer-term trend resistance on the TSX in CAD.

WELL.TO stock: Earnings preview and what to expect on 19 Mar 2026

WELL.TO earnings are due 19 Mar 2026, and the market will focus on revenue growth, adjusted EBITDA margins, and commentary on WELLSTAR’s spin-out timing. Management has flagged WELLSTAR revenue run-rate near C$84.00 million and a target to reach C$100.00 million by year-end, which investors may treat as material guidance.

We expect analysts to probe billing services margin expansion and the impact of the recent acquisitions (PatientSERV and Lambert) that add roughly C$5.00 million in annual revenue. Strong margin commentary could lift the multiple; weak cash flow metrics may keep shares under pressure.

WELL.TO stock: Financials, valuation and key metrics

WELL Health shows mixed fundamentals: TTM revenue per share is 4.76, book value per share is 3.92, and EPS is negative at -0.09. Price ratios include a P/S of 0.90 and a P/B of 1.29. Enterprise value to sales is 1.35, while enterprise value over EBITDA is 20.17, indicating a stretched multiple versus near-term profitability.

Balance-sheet and cash flow signals deserve attention: debt-to-equity is 0.74, current ratio is 0.92, and interest coverage is weak at 0.08. Operating and free cash flow per share are negative, which increases sensitivity to execution on cost controls and integration synergies.

WELL.TO stock: Corporate strategy, WELLSTAR spin-out and recent M&A

WELL Health is advancing a strategic spin-out of WELLSTAR and completed two billing acquisitions that expand coverage to six provinces and add an estimated C$5.00 million in annual revenue. Management highlighted a C$62.00 million equity financing to fund WELLSTAR growth and an aim for a C$100.00 million run-rate.

The WELLSTAR thesis centers on data network effects and billing automation. Progress on the spin-out timeline and proof of incremental EBITDA from the billing deals will be central to valuation uplift. For the official release, see the company statement source and the company profile source.

WELL.TO stock: Technical setup and trading signals

Technically, WELL.TO shows neutral momentum. RSI is 46.52, MACD histogram is flat, and ADX at 19.90 indicates no clear trend. Bollinger Bands middle band is C$4.13 with a lower band at C$3.73 and upper band at C$4.52, placing current price near the middle band.

Short-term support near C$4.00 and resistance near C$4.50–C$4.60 define a trading range. Traders should watch volume spikes around the earnings date and any clear MACD crossover for directional confirmation.

WELL.TO stock: Risks, opportunities and analyst view

Key opportunities include WELLSTAR monetization, cross-selling billing services, and margin improvement from scale. The company’s network of clinics and EMR footprint support long-term growth potential. Financial growth metrics showed revenue growth of 18.51% in the last fiscal year, indicating demand for its services.

Risks are execution on spin-out timing, high net debt relative to EBITDA (net debt to EBITDA at 6.71), weak cash flow conversion, and regulatory exposure in healthcare. Recent third-party rating data shows mixed signals; investors should weigh near-term cash metrics against the strategic roadmap.

Final Thoughts

WELL.TO stock closed at C$4.27 on 17 Mar 2026 with above-average volume as investors prepare for the 19 Mar 2026 earnings report. The upcoming release is likely to move the stock through clarity on WELLSTAR progress, acquisition synergies, and margin guidance. Meyka AI’s grade and forecast add disciplined context: Meyka AI rates WELL.TO with a score out of 100 as 68.07 (Grade B, HOLD). This grade factors in S&P 500 and sector comparisons, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a one-year price of C$4.27, essentially in line with the current price of C$4.27, implying near-term flat performance of 0.00%. For scenario planning, we model a conservative price target of C$3.50 and a bullish target of C$6.00 based on WELLSTAR execution and margin expansion. Forecasts are model-based projections and not guarantees. For active traders we recommend watching cash flow indicators and the WELLSTAR spin-out timetable; longer-term investors should weigh strategic upside against cash conversion and leverage risks. More details and real-time updates are available at the Meyka AI stock page for WELL.TO: WELL.TO at Meyka.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.